Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review

Table 1 Characteristics of RBC-containing triple and quadruple therapies.

Refs	Combination regimens	Dose	Treatment duration	Eradication rate (ITT)		P
				PUD	NUD
				N/T.N (%)	N/T.N (%)
	Triple therapies
	RBCCA
6	RBC/Cla/Amo	400 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7 d	20/23 (86.96)	18/22 (81.8)
15	RBC/Cla/Amo	400 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7 d	13/18 (72.2)	48/57 (84.2)
16	RBC/Cla/Amo	400 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7 d	19/23 (82.6)	66/76 (86.8)
	Others			52/64 (81.3)	132/155 (85.2)1
13	RBC/Cla/Tin	400 mg b.i.d./500 mg b.i.d./500 mg b.i.d.	5 d	20/27 (74.1)	23/39 (58.97)	0.32
9	RBC/Cla/Tin	400 mg b.i.d./500 mg b.i.d./500 mg b.i.d.	5 d	6/9 (66.7)	9/12 (75)	0.95
16	RBC/Cla/Met	400 mg b.i.d./500 mg b.i.d./400 mg b.i.d.	7 d	20/21 (95.2)	69/78 (88.5)	0.61
16	RBC/Met/Tet	400 mg b.i.d./400 mg b.i.d./1 g b.i.d.	7 d	38/46 (82.6)	43/54 (79.6)	0.9
14	RBC/Fur/Tet	350 mg b.i.d./100 mg b.i.d./500 mg b.i.d.	7 d	20/24 (83.3)	31/36 (86.1)	0.94
14	RBC/Fur/Amo	350 mg b.i.d./100 mg b.i.d./1 g b.i.d.	7 d	15/19 (78.95)	34/41 (82.9)	0.99
	Quadruple therapy
6	RBC/Cla/Amo/Met	400 mg b.i.d./400 mg b.i.d./1 g b.i.d./500 mg b.i.d.	5 d	174/174 (100)	62/71 (87.3)	<0.05

RBC, ranitidine bismuth citrate; Cla, clarithromycin; Tin, tinidazole; Fur, furazolidone; Tet, tetracycline; Amo, amoxicillin; Met, metronidazole; b.i.d., twice daily; PUD, peptic ulcer disease; NUD, non-ulcer dyspepsia; N/T.N, number/total number.

¹Relative risk: 0.96 (95%CI 0.84-1.11).